La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Pharming Group Croissance future

Future contrôle des critères 4/6

Pharming Group devrait augmenter ses bénéfices et son chiffre d'affaires de 60.1% et de 9.7% par an respectivement. Le BPA devrait croître de de 69.9% par an. Le rendement des capitaux propres devrait être 4% dans 3 ans.

Informations clés

64.6%

Taux de croissance des bénéfices

73.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	35.7%
Taux de croissance des recettes	9.7%
Rendement futur des capitaux propres	4.0%
Couverture par les analystes	Low
Dernière mise à jour	26 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?

Mar 15

Prévisions de croissance des bénéfices et des revenus

ENXTAM:PHARM - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	369	22	13	10	4
12/31/2025	326	-1	1	-4	4
12/31/2024	298	-11	14	20	4
6/30/2024	278	-13	-6	-6	N/A
3/31/2024	258	-11	18	-2	N/A
12/31/2023	245	-11	3	-17	N/A
9/30/2023	219	-22	-4	-24	N/A
6/30/2023	206	-16	5	-15	N/A
3/31/2023	202	-2	-3	-1	N/A
12/31/2022	206	14	20	22	N/A
9/30/2022	204	30	25	33	N/A
6/30/2022	202	21	15	26	N/A
3/31/2022	202	11	17	31	N/A
12/31/2021	199	16	21	38	N/A
9/30/2021	200	22	29	43	N/A
6/30/2021	200	31	40	52	N/A
3/31/2021	202	37	59	70	N/A
12/31/2020	212	38	68	84	N/A
9/30/2020	212	44	70	85	N/A
6/30/2020	202	46	59	93	N/A
3/31/2020	202	42	53	84	N/A
1/1/2020	189	41	49	74	N/A
9/30/2019	175	38	48	70	N/A
6/30/2019	175	34	59	63	N/A
3/31/2019	158	29	54	57	N/A
12/31/2018	155	29	42	46	N/A
9/30/2018	152	-29	57	63	N/A
6/30/2018	138	-44	54	61	N/A
3/31/2018	128	-80	N/A	52	N/A
12/31/2017	108	-91	N/A	46	N/A
9/30/2017	76	-53	N/A	14	N/A
6/30/2017	47	-47	N/A	-6	N/A
3/31/2017	31	-21	N/A	-13	N/A
12/31/2016	17	-18	N/A	-11	N/A
9/30/2016	12	-16	N/A	-18	N/A
6/30/2016	12	-15	N/A	-18	N/A
3/31/2016	13	-14	N/A	-18	N/A
12/31/2015	12	-11	N/A	-19	N/A
9/30/2015	29	8	N/A	-3	N/A
6/30/2015	27	9	N/A	-1	N/A
3/31/2015	23	10	N/A	-3	N/A
12/31/2014	26	-7	N/A	-3	N/A
9/30/2014	6	-29	N/A	-19	N/A
6/30/2014	6	-35	N/A	-16	N/A
3/31/2014	11	-35	N/A	-14	N/A
12/31/2013	9	-21	N/A	-11	N/A
9/30/2013	19	-15	N/A	-8	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PHARM devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 1% ).

Bénéfices vs marché: PHARM devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: PHARM devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PHARM ( 9.7% par an) devrait croître plus rapidement que le marché Dutch ( 9.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PHARM ( 8.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de PHARM devrait être faible dans 3 ans ( 4 %).

Pharming Group Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 7.8% to €1.78

Pharming Group N.V. Provides Revenue Guidance for 2024

Price target increased by 11% to €2.00

Consensus estimates of losses per share improve by 31%

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

Recent updates

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Consensus revenue estimates fall by 14%

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €1.80

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Now 21% undervalued after recent price drop

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe